AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Jun 4, 2021
29864_dirs_2021-06-04_35d43dc6-78a2-4b94-9caf-2caea562499e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-06-02
Reporting Person: Bhatia Sangeeta N. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-02 | Common Stock | S | 285 | $208.96 | Disposed | 5465 | Direct |
| 2021-06-02 | Common Stock | S | 153 | $210.01 | Disposed | 5312 | Direct |
| 2021-06-02 | Common Stock | S | 121 | $211.00 | Disposed | 5191 | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $208.96 (range $208.64 to $209.48).
F3: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $210.01 (range $209.64 to $210.34).
F5: Open market sales reported on this line occurred at a weighted average price of $211.00 (range $210.70 to $211.50).